Cargando…

A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin

Fournier's gangrene (FG) is a rare but severe infection in the soft tissue, leading to necrosis in the perineum, perianal and genitourinary area. This infection can spread rapidly in the body and lead to multi-organ failure, septic shock, and death. This life-threatening infection is usually ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jahir, Tahmina, Hossain, Sadaf, Bagum, Mobasera, Saidi, Ahmed, Risal, Ruby, Schmidt, Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Endocrinology/Diabetes/Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576122/ https://www.ncbi.nlm.nih.gov/pubmed/36262942 http://dx.doi.org/10.7759/cureus.29264

Ejemplares similares

Fournier’s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy
por: Chowdhury, Tutul, et al.
Publicado: (2022)

Cocaine Hurts Your Kidneys Too: A Rare Case of Acute Interstitial Nephritis Caused by Cocaine Abuse
por: Jahir, Tahmina, et al.
Publicado: (2021)

THU282 Improved Fournier’s Gangrene Outcomes With Prior SGLT2i Or Metformin Usage
por: Venugopal, Sharini, et al.
Publicado: (2023)

PSUN259 A Severe Case of Fournier's Gangrene Associated With Dapagliflozin
por: Syed, Shumail, et al.
Publicado: (2022)

LBSUN291 Fournier's Gangrene In A Diabetic Male Taking Dapagliflozin
por: Patel, Janki M, et al.
Publicado: (2022)

RF16 | PSUN170 Prevalence of Fournier's Gangrene in T2DM Treated with Oral Antiglycemic Medications
por: Engel, Ashley, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

SUN-700 Fournier’s Gangrene and Diabetic Ketoacidosis Caused by Canagliflozin
por: Stamatiades, George Alexiades, et al.
Publicado: (2020)

Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Case Report and Review of Literature
por: Aggarwal, Ankita, et al.
Publicado: (2020)

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

Fournier’s Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Life-Threatening Complications
por: Kasbawala, Kinjal, et al.
Publicado: (2020)

Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
por: Maradia, Jay, et al.
Publicado: (2023)

A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Patel, Khyati, et al.
Publicado: (2022)

Fournier’s Gangrene in an HIV-Positive Patient on Empagliflozin for the Treatment of Diabetes Mellitus
por: Khokhar, Farzam, et al.
Publicado: (2022)

Differential effect of canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice
por: Otsuka, Hiroko, et al.
Publicado: (2022)

Fournier’s Gangrene under Sodium–Glucose Cotransporter-2 Inhibitors Therapy in Gynecological Patients
por: Serrano Olave, Adriana, et al.
Publicado: (2022)

Fournier's Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience
por: Dass, Ashwitha S., et al.
Publicado: (2019)

Fournier Gangrene
por: Wolf, Chelsea T., et al.
Publicado: (2010)

Fournier’s gangrene
por: Cheung, Phoebe S. Y., et al.
Publicado: (2009)

Fournier gangrene
por: Parry, Nadiah
Publicado: (2015)

Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
por: Yang, Jeff Yufeng, et al.
Publicado: (2020)

Fournier’s Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Empagliflozin: A Case Report
por: Nagano, Yasunori, et al.
Publicado: (2019)

SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study
por: Wang, Tongtong, et al.
Publicado: (2020)

Fournier’s gangrene under SGLT-2 inhibitor therapy: A literature review and case report
por: Ellegård, Lisa, et al.
Publicado: (2020)

Fournier´s Gangrene Under Sodium-Glucose Cotransporter 2 Inhibitor Therapy as a Life-Threatening Adverse Event: A Case Report and Review of the Literature
por: Rodler, Severin, et al.
Publicado: (2019)

The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes
por: Shami, Dalia, et al.
Publicado: (2023)

Fournier's Gangrene: Report of 2 Cases
por: Hota, Prasan Kumar
Publicado: (2012)

LBSUN290 A Rare, Sordid Tale Of The Two Most Dreaded Adverse Effects Of SGLT-2 Inhibitors Occurring Concurrently - Acute Pancreatitis And Euglycemic Diabetic Ketoacidosis - Within Days Of Initiating Empagliflozin Therapy.
por: Arora, Gunjan, et al.
Publicado: (2022)

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Masked Primary Hyperparathyroidism by Empagliflozin Use
por: Awada, Mariam, et al.
Publicado: (2022)

Ultrasound in the diagnosis of Fournier's gangrene
por: Kube, Erika, et al.
Publicado: (2012)

Fournier's Gangrene: Current Practices
por: Mallikarjuna, M. N., et al.
Publicado: (2012)

A Case of Fournier's Gangrene
por: Kordahi, Anthony Maurice, et al.
Publicado: (2017)

Massive necrotizing Fournier's gangrene
por: Rivera-Alvarez, Fernando, et al.
Publicado: (2021)

Ultrasonic Debridement of Fournier Gangrene
por: Tanuma, Takahiro, et al.
Publicado: (2023)

Effectiveness of Empagliflozin With Vitamin D Supplementation in Peripheral Neuropathy in Type 2 Diabetic Patients
por: Mehta, Sanjana, et al.
Publicado: (2021)

THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023)

THU360 Hyperglycemic DKA In Patient On Monotherapy With SGLT-2 Inhibitor
por: Ahmed, Samihah, et al.
Publicado: (2023)

Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis complicating the perioperative management of a patient with type 2 diabetes mellitus (T2DM) and Fournier’s gangrene: A case report
por: Lindsay, Patrick J., et al.
Publicado: (2020)

RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f0sp149hf00gli0etdi2uq8sn3